News | Remote Monitoring | January 18, 2017

LindaCare Expands Remote Patient Monitoring Operations to the U.S.

Company plans to provide data gathering and analysis services to complement web-based software platform for remote monitoring of cardiac implantable electronic devices

LindaCare, expansion, remote patient monitoring, CIEDs, cardiac implantable electronic devices, United States

January 18, 2017 — LindaCare announced that it will open a new customer support facility in Connecticut to support growing interest in their vendor-neutral software platform for monitoring patients with chronic heart disease and other conditions.

The announcement of the launch into the U.S. market follows substantial interest in LindaCare's solutions at the Heart Rhythm Society conference last year, the company said. The award of a $500,000 investment from Connecticut Innovations (CI) following success in their VentureClash investment challenge has allowed LindaCare to accelerate their plans to invest beyond their European base.

LindaCare’s first version of the product is a web-based software platform for the remote monitoring of patients with cardiac implantable electronic devices (CIEDs) and suffering from chronic heart failure (CHF) and cardiac arrhythmia; this accounts for an estimated total of about 10 million patients worldwide today.

The Connecticut office will initially comprise four sales and customer support professionals, with a planned rollout of further, localized support across the United States later in the year, bringing immediate access to high-quality support across multiple time zones.

In parallel, LindaCare is planning to provide Independent Diagnostic and Testing Facility (IDTF) patient monitoring services through accredited local service providers. These services will help to gather and analyze the remote data, thereby allowing busy medical professionals to focus on diagnosis and care of patients.

Miguel Maquieira, CTO and co-founder of LindaCare, indicated that a significant research and development phase is completing and the U.S. expansion will allow a new software suite and service model to be announced simultaneously in Europe and the U.S. in the next few weeks.

For more information: www.lindacare.com

Related Content

World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...
Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
Overlay Init